B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome

WH Fridman, M Meylan, F Petitprez, CM Sun… - Nature reviews Clinical …, 2022 - nature.com
B cells are a major component of the tumour microenvironment, where they are
predominantly associated with tertiary lymphoid structures (TLS). In germinal centres within …

Systemic immunity in cancer

KJ Hiam-Galvez, BM Allen, MH Spitzer - Nature reviews cancer, 2021 - nature.com
Immunotherapy has revolutionized cancer treatment, but efficacy remains limited in most
clinical settings. Cancer is a systemic disease that induces many functional and …

Overcoming TGFβ-mediated immune evasion in cancer

DVF Tauriello, E Sancho, E Batlle - Nature Reviews Cancer, 2022 - nature.com
Transforming growth factor-β (TGFβ) signalling controls multiple cell fate decisions during
development and tissue homeostasis; hence, dysregulation of this pathway can drive …

Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders

NA Maskalenko, D Zhigarev… - Nature reviews Drug …, 2022 - nature.com
Natural killer (NK) cells have crucial roles in the innate immunosurveillance of cancer and
viral infections. They are 'first responders' that can spontaneously recognize abnormal cells …

NK cells for cancer immunotherapy

N Shimasaki, A Jain, D Campana - Nature reviews Drug discovery, 2020 - nature.com
Natural killer (NK) cells can swiftly kill multiple adjacent cells if these show surface markers
associated with oncogenic transformation. This property, which is unique among immune …

Tumor-infiltrating natural killer cells

B Cózar, M Greppi, S Carpentier… - Cancer …, 2021 - aacrjournals.org
Because of their potent antitumor activity and their proinflammatory role, natural killer (NK)
cells are at the forefront of efforts to develop immuno-oncologic treatments. NK cells …

Emerging targeted therapies for HER2-positive breast cancer

MF Mercogliano, S Bruni, FL Mauro, R Schillaci - Cancers, 2023 - mdpi.com
Simple Summary HER2-positive breast cancer (BC), which accounts for~ 20% of BC, is one
of the more aggressive and has the worst overall survival rate among them. These patients …

[HTML][HTML] Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells

P André, C Denis, C Soulas, C Bourbon-Caillet… - Cell, 2018 - cell.com
Checkpoint inhibitors have revolutionized cancer treatment. However, only a minority of
patients respond to these immunotherapies. Here, we report that blocking the inhibitory …

Natural killer cells and other innate lymphoid cells in cancer

L Chiossone, PY Dumas, M Vienne… - Nature Reviews …, 2018 - nature.com
Immuno-oncology is an emerging field that has revolutionized cancer treatment. Most
immunomodulatory strategies focus on enhancing T cell responses, but there has been a …

CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors

L Peng, G Sferruzza, L Yang, L Zhou… - Cellular & Molecular …, 2024 - nature.com
In the past decade, chimeric antigen receptor (CAR)-T cell therapy has emerged as a
promising immunotherapeutic approach for combating cancers, demonstrating remarkable …